100 consecutive orthopedic cases demonstrate the use of force-modulating tissue bridges across ACL, knee, shoulder, elbow and ankle procedures.
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ — BRIJ Medical today announced the publication of a new 100-case clinical study evaluating Brijjit® Force-Modulating Tissue Bridges for postoperative incision management in sports medicine. Published in the Journal of Orthopaedic Experience & Innovation, the retrospective study reports zero (0) documented cases of wound dehiscence, delayed healing, surgical site infection, allergic dermatitis, adhesive-related skin injury or wound-related reoperation across 100 consecutive outpatient procedures.
Study Design:
The study was designed to address a practical clinical question: Can postoperative incision management help avoid the allergic skin reactions associated with cyanoacrylate closure while supporting the incision during early healing and patient movement?
Traditional closure brings the skin edges together—but what happens to the incision after the patient leaves the OR?
Conducted by John A. Grotting, MD, and Ege Karadag, the study evaluated 100 consecutive sports medicine procedures performed by a single surgeon between January 2023 and December 2025. Brijjits were used to provide tension reduction and wound support across multiple procedures and anatomical sites, including the knee, shoulder, and elbow.
Orthopedic incisions face a unique challenge: they are healing while patients are already moving. Brijjit is designed to actively offload tension by up to 100%, helping address the mechanical forces placed on the incision during early recovery and range of motion.
“We’ve traditionally focused on how to close an incision,” said Dr. Grotting. “The next question is what happens to that incision once the patient starts moving. Force-modulating tissue bridges give us a non-invasive way to actively offload tension and address the mechanical forces acting on a healing incision while maintaining the surgical and rehabilitation protocols we already use. It’s an easy-to-use insurance policy that secures my work and helps my patients heal beautifully.”
Study Findings: Zero documented wound or adhesive-related complications
Across the 100 cases, the study reported no documented allergic dermatitis, wound dehiscence, delayed healing, surgical site infection, mechanical skin reaction or wound-related reoperation. The findings provide an early clinical experience supporting the feasibility of force-modulating incision management in outpatient sports medicine and orthopedic surgery.
Patients generally tolerated Brijjit well, with no reported restriction in range of motion or need to modify postoperative bracing or rehabilitation protocols. Two early device detachments occurred during the learning curve, neither resulting in complications nor disruption to rehabilitation.
Growing clinical evidence
The publication adds to BRIJ Medical’s growing body of clinical experience with Brijjit and expands its evidence base into sports medicine and orthopedic incision management.
“Research is at the heart of what we’re doing,” said Dr. Felmont “Monte” Eaves, Founder and Chief Medical Officer at BRIJ Medical. “We’re deeply committed to studying these technologies and continuing to build the evidence around them, and the data coming forward is increasingly validating what we’re seeing clinically. There’s much more to learn—and much more data to come. It’s an exciting time for this technology and for the patients and surgeons we’re committed to helping.”
The full study, “Force-Modulating Tissue Bridges in Sports Medicine Incision Management: A First 100-Case Experience Evaluating Allergic Reactions and Postoperative Complications,“ is published in Volume 7, Issue 2 of the Journal of Orthopaedic Experience & Innovation.
Publication of the study in JOEI does not imply endorsement of, or recommendation for, any specific product or technology referenced in the study.
Citation: Grotting, John A, and Ege Karadag. 2026. “Force-Modulating Tissue Bridges in Sports Medicine Incision Management: A First 100-Case Experience Evaluating Allergic Reactions and Postoperative Complications.” Journal of Orthopaedic Experience & Innovation 7 (2). https://doi.org/10.60118/001c.165283.
ABOUT BRIJ MEDICAL
BRIJ Medical is advancing wound closure with technologies designed to help patients and surgeons achieve better outcomes at every stage of healing.
Our portfolio is designed to seal incisions, protect outcomes, offload tension, and heal with confidence. BRIJ-SEAL™ is a hypoallergenic, advanced wound sealant that provides a 14-day bacterial barrier, helping protect the incision during the critical early healing period. Brijjit® is an active tension offloading device clinically shown to eliminate up to 100% of incision tension, reduce wound breakdown by 90%*, and reduce scar area by 38%.*
Trusted by surgeons across the U.S. and Canada, BRIJ Medical brings greater control to incision closure—and greater confidence to healing.
Learn more at www.BRIJmedical.com.
*Clinical data available on BRIJ Medical’s website: Clinical Evidence – BRIJ Medical
View original content to download multimedia:https://www.prnewswire.com/news-releases/100-consecutive-sports-medicine-cases-zero-documented-wound-complications-with-brijjit-tissue-bridges-302886416.html
SOURCE BRIJ Medical
